Novo Nordisk Limits Supply of Wegovy Amid High Demand
TL;DR Summary
Novo Nordisk is limiting the supply of low doses of obesity medication Wegovy in the U.S. due to high demand. The company is still supplying limited quantities of the drug to wholesalers for distribution to retail pharmacies. Wegovy was approved by the FDA in 2021 as a weight management treatment medication and belongs to a class of drugs called GLP-1 agonists. The drug has become popular in the weight loss industry, and endorsements by celebrities on social media have fueled shortages nationwide.
Topics:business#drugs#food-and-drug-administration#health#novo-nordisk#wegovy#weight-loss-management
- Distributor limiting allocation of low dose Wegovy The Hill
- Novo Nordisk limits Wegovy doses for new patients as demand outpaces supply CNN
- Wegovy US Supply Shortage Strikes Again Medscape
- Drugmaker Norvo Nordisk limits obesity drug Wegovy in U.S. UPI News
- Novo Nordisk cuts supply of certain Wegovy doses as it faces strong demand Fox Business
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
1 min
vs 2 min read
Condensed
71%
281 → 82 words
Want the full story? Read the original article
Read on The Hill